experience, having served on multiple boards including Mast Therapeutics, La Jolla Pharmaceutical (acquired in 2022), and currently Exuma Biotech. His willingness to deploy capital in this difficult environment suggests he sees potential in Savara's pipeline.
Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Its lead candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor currently in Phase 3 development for autoimmune

pulmonary alveolar proteinosis, a rare lung condition with limited treatment options.
While early-stage biotech investments remain highly speculative, insider purchases in this challenging environment warrant attention, especially from directors with deep industry experience like Ramsay.
Are you finding selective opportunities in the beaten-down biotech sector, or staying clear until market sentiment improves? Do insider buys influence your decisions in this high-risk space? 🤔